Regional Analysis

Global Cell and Gene Therapy Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global cell and gene therapy market over the forecast period. This is attributed to the increasing product/ platform launch by market players. For instance, in October 2022, Allogene Therapeutics, Inc., a clinical-stage biotechnology company, announced the launch of CAR T Together, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.

Furthermore, in December 2021, Novartis, a pharmaceutical company, announced the introduction of T-Charge, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. Furthermore, the company stated that Novartis will present early clinical data from ongoing Phase I clinical trials with YTB323 (anti-CD19) and PHE885 (anti-BCMA), the first Novartis CAR-T cell therapies developed using this platform.

Global Cell and Gene Therapy Market Cross Sectional Analysis:

Increasing investments by the key market players for the expansion of their capabilities in advancing gene therapy are driving the growth of the therapy type segment in North America. For instance, in December 2021, Pfizer Inc., a pharmaceutical company, announced that it had been investing US$ 800 billion to build manufacturing facilities supporting gene therapy manufacturing from preclinical research through commercial scale production. These three plants based in North Carolina highlight the substantial investments that will be required to scale up cell and gene therapies for broad market distribution.